会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Method of purifying glucose isomerase and a composition for storing same
    • 葡萄糖异构酶的纯化方法及其组合物
    • US4237231A
    • 1980-12-02
    • US93570
    • 1979-11-13
    • Denise M. JacksonYoshihisa Tsuda
    • Denise M. JacksonYoshihisa Tsuda
    • C12N9/92C12N9/96
    • C12N9/92C12N9/96Y10S435/814Y10S435/816Y10S435/827Y10S435/853Y10S435/886Y10S435/89
    • A process for purifying glucose isomerase comprises the steps of acid treatment and salt fractionation. An enzyme solution is treated with an acid, such as acetic acid, to a pH from about 3.5 to about 5.0. The proteinaceous solids are collected and extracted with a buffer, such as imidazole, whose solution has a pH of about 6 to about 8. The solution is then collected and a salt, such as ammonium sulfate, is dissolved therein from about 40% to about 50% of its saturation point. The proteinaceous solids which form are removed and additional ammonium sulfate is dissolved to attain from about 41% to about 60% of its saturation point, followed by collection of the solids containing purified enzyme. A composition which preserves enzyme activity upon storage of glucose isomerase and which imparts resistance to thermal deactivation of said enzyme comprises an aqueous solution of glycerol, a buffer whose solution is at a pH of about 6 to about 8, divalent cobalt ions and magnesium ions.
    • 葡萄糖异构酶的纯化方法包括酸处理和盐分离步骤。 用酸(如乙酸)处理酶溶液至约3.5至约5.0的pH。 收集蛋白质固体并用缓冲液如咪唑提取其溶液,其pH为约6至约8.然后收集溶液,并将盐如硫酸铵溶解在其中约40%至约 其饱和点的50%。 除去形成的蛋白质固体并加入另外的硫酸铵以达到其饱和点的约41%至约60%,然后收集含有纯化酶的固体。 保存葡萄糖异构酶并赋予对所述酶的热失活抗性的酶活性的组合物包含甘油水溶液,其溶液的pH为约6至约8的缓冲液,二价钴离子和镁离子。
    • 7. 发明授权
    • Glycoside-hydrolase enzyme inhibitors
    • 糖苷 - 水解酶抑制剂
    • US4013510A
    • 1977-03-22
    • US493463
    • 1974-07-31
    • Werner FrommerWalter PulsDietmar SchaferDelf Schmidt
    • Werner FrommerWalter PulsDietmar SchaferDelf Schmidt
    • C12P1/04C12P1/06C12D13/00
    • A61K31/70C12P1/04C12P1/06Y10S435/803Y10S435/822Y10S435/827Y10S435/886Y10S435/889Y10S435/896Y10S435/907Y10S435/911
    • This invention relates to inhibitors for glycosidehydrolases derived from bacteria of the order Actinomycetales, means for their production comprising cultivation of a microorganism of the order Actinomycetales in appropriate nutrient solutions under conditions most favorable to growth and production of the enzyme inhibitor and recovering, as a new product, glycoside-hydrolase enzyme inhibitors, from the culture as well as the use of said enzyme inhibitors in pharmaceutically acceptable therapeutic compositions in the treatment of conditions indicating obesity, diabetes, pre-diabetes, gastritis, gastric ulcer, hyperlipidemia (arteriosclerosis) and the like. The invention also contemplates the provision of methods of inhibiting the reaction of carbohydrates and glycoside-hydrolase enzymes and particularly carbohydrate-splitting glycoside-hydrolase enzymes of the digestive tract by means of conducting said reaction of said carbohydrates and glycoside-hydrolase enzymes in the presence of a glycoside-hydrolase enzyme inhibitor for said glycoside-hydrolase enzyme derived from a strain of microorganism of the order Actinomycetales. The invention further contemplates the provision of methods for the treatment of indications of the group consisting of obesity, adipose, hyperlipidemia (arteriosclerosis), diabetes, pre-diabetes, gastritis, gastric ulcer, duodenal ulcer, and caries induced by the action of glycoside-hydrolase enzymes and carbohydrates, the improvement which comprises employing an enzyme inhibitor for glycoside-hydrolase enzymes produced by a strain of microorganism of the order Actinomycetales.
    • 本发明涉及来自放线菌纲序列的细菌的糖苷水解酶的抑制剂,其生产方法包括在最有利于生长和产生酶抑制剂的条件下,在适当的营养液中培养放线菌纲的微生物,并作为新的 产品,糖苷 - 水解酶抑制剂,以及所述酶抑制剂在药学上可接受的治疗组合物中用于治疗指示肥胖,糖尿病,前期糖尿病,胃炎,胃溃疡,高脂血症(动脉硬化)和 喜欢。 本发明还考虑提供通过在所述碳水化合物和糖苷 - 水解酶的存在下进行所述碳水化合物和糖苷 - 水解酶的反应来抑制碳水化合物和糖苷 - 水解酶,特别是消化道的碳水化合物 - 裂解糖苷 - 水解酶的反应的方法 一种衍生自放线菌纲的微生物菌株的糖苷 - 水解酶的糖苷 - 水解酶抑制剂。 本发明进一步考虑了提供治疗由肥胖,脂肪,高脂血症(动脉硬化),糖尿病,前期糖尿病,胃炎,胃溃疡,十二指肠溃疡以及由糖苷 - 水解酶和碳水化合物,其改进包括使用由抑制放线菌的微生物菌株产生的糖苷 - 水解酶的酶抑制剂。